Carl Zeiss Meditec (AFX) AI Stock Analysis

Carl Zeiss Meditec

(Six Swiss:AFX)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Balance Sheet StrengthLow leverage and a robust equity ratio provide Carl Zeiss Meditec with financial resilience. This supports continued investment in ophthalmology and microsurgery products, gives management flexibility during weaker demand, and reduces the balance-sheet pressure associated with funding operations or growth.

Negative Factors

Revenue Growth PressureThe reported negative revenue-growth measure signals current top-line pressure and raises questions about near-term demand, commercial execution, or the pace of procedure-related equipment purchases. If sustained, slower sales would limit operating leverage and make future profit recovery more difficult.

Carl Zeiss Meditec (AFX) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 2.88B
Dividend Yield: 1.52%
Average Volume (3M): 550
Price to Earnings (P/E): 20.9
Beta (1Y): 0.18
Revenue Growth: -2.34%
EPS Growth: -40.09%
Country: Switzerland
Employees: 5,784
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Carl Zeiss Meditec Business Overview & Revenue Model

Company Description

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis...

Carl Zeiss Meditec Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

CH:AFX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:EUZ	69Neutral	EUR 832.23M	16.63	19.49%	1.65%	4.42%	35.68%
DE:JEN	68Neutral	EUR 2.22B	25.55	8.68%	1.03%	-2.11%	12.80%
DE:DRW8	67Neutral	EUR 1.64B	11.28	10.20%	2.93%	5.06%	40.18%
DE:SRT	62Neutral	EUR 18.00B	72.47	7.81%	0.32%	4.19%	63.32%
DE:SBS	57Neutral	EUR 273.51M	-562.50	-0.17%	2.67%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

CH:AFX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:AFX	Carl Zeiss Meditec	32.04	-138.47	-81.21%
DE:DRW8	Draegerwerk AG & Co. KGaA (0MT8)	75.40	15.88	26.67%
DE:EUZ	Eckert & Ziegler Strahlen und Medizintechnik	13.30	-3.09	-18.88%
DE:JEN	Jenoptik AG	38.84	19.79	103.85%
DE:SRT	Sartorius (0NIQ)	229.00	46.59	25.54%
DE:SBS	STRATEC Biomedical	22.50	0.32	1.43%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Carl Zeiss Meditec AI Stock Analysis